Roche stock in focus: Goldman flips to Neutral, UBS lifts target as Jan 29 results loom
Roche shares closed up 0.93% at 348.90 Swiss francs on Friday, near a 52-week high. Goldman Sachs upgraded the stock to Neutral and raised its target to 365 francs, citing clinical milestones in 2026. UBS kept its Buy rating and lifted its target to 384 francs. Investors await Roche’s full-year results on Jan. 29.